Ruxolitinib in Dermatology: A Review of its Uses in Cutaneous Disorders
Neerja Saraswat, Durga Madhab Tripathy, Shekhar Neema, Santanu Banerjee, Vikas Pathania, Sushil Kumar, Anirudh TripathyAbstract
Recent studies have highlighted the role of the JAK/STAT signalling pathway in chronic skin conditions such as atopic dermatitis, vitiligo, alopecia areata, lichen planus, and various granulomatous disorders like sarcoidosis, necrobiosis lipoidica, and granuloma annulare. Ruxolitinib is a first-generation JAK inhibitor that the US Food and Drug Administration approved for treating intermediate or high-risk myelofibrosis in 2011. Recently, the topical formulation has been approved to manage mild to moderate atopic dermatitis and non-segmental vitiligo in adults. Encouraging results have been demonstrated with topical ruxolitinib in multiple other skin diseases. This review provides a comprehensive analysis of the use of ruxolitinib in dermatological conditions through a PubMed literature search.